- Home
- ARQT vs SRCE Comparison
ARQT vs SRCE Comparison
Compare ARQT & SRCE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- SRCE
- Stock Information
- Founded
- ARQT 2016
- SRCE 1863
- Country
- ARQT United States
- SRCE United States
- Employees
- ARQT N/A
- SRCE N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- SRCE Major Banks
- Sector
- ARQT Health Care
- SRCE Finance
- Exchange
- ARQT Nasdaq
- SRCE Nasdaq
- Market Cap
- ARQT 1.7B
- SRCE 1.5B
- IPO Year
- ARQT 2020
- SRCE N/A
- Fundamental
- Price
- ARQT $15.99
- SRCE $64.08
- Analyst Decision
- ARQT Strong Buy
- SRCE Hold
- Analyst Count
- ARQT 7
- SRCE 3
- Target Price
- ARQT $19.00
- SRCE $72.00
- AVG Volume (30 Days)
- ARQT 1.8M
- SRCE 79.3K
- Earning Date
- ARQT 08-06-2025
- SRCE 07-24-2025
- Dividend Yield
- ARQT N/A
- SRCE 2.49%
- EPS Growth
- ARQT N/A
- SRCE 10.56
- EPS
- ARQT N/A
- SRCE 5.70
- Revenue
- ARQT $263,464,999.00
- SRCE $391,814,000.00
- Revenue This Year
- ARQT $61.83
- SRCE $16.66
- Revenue Next Year
- ARQT $36.55
- SRCE $1.40
- P/E Ratio
- ARQT N/A
- SRCE $11.24
- Revenue Growth
- ARQT 99.50
- SRCE 6.91
- 52 Week Low
- ARQT $8.03
- SRCE $52.14
- 52 Week High
- ARQT $17.75
- SRCE $68.13
- Technical
- Relative Strength Index (RSI)
- ARQT 56.88
- SRCE 62.52
- Support Level
- ARQT $15.43
- SRCE $60.96
- Resistance Level
- ARQT $17.29
- SRCE $62.06
- Average True Range (ATR)
- ARQT 0.97
- SRCE 1.24
- MACD
- ARQT 0.06
- SRCE 0.41
- Stochastic Oscillator
- ARQT 63.70
- SRCE 95.99
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About SRCE 1st Source Corporation
1st Source Corp, along with its subsidiary, offers banking services. The bank provides Commercial, Agricultural, and Real Estate Loans, which are given to privately owned business clients mainly located within the regional market areas, Consumer Services that consist of the full range of consumer banking products and services, Trust and Wealth Advisory Services, and Insurance services to individuals and business clients. Its Specialty Finance Group offers financing services for construction equipment, new and pre-owned private and cargo aircraft, and various vehicle types for fleet purposes.